ArticleBMC bioinformatics2005
An integrated approach of immunogenomics and bioinformatics to identify new Tumor Associated Antigens (TAA) for mammary cancer immunological prevention.
Article in BMC bioinformatics, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 35 citations in OpenAlex.
- Research progress in the role and mechanism of GALNT3 in human diseases (Review).Biomedical reports · 2026Review
- YY1-mediated reticulocalbin-2 upregulation promotes the hepatocellular carcinoma progression via activating MYC signaling.American journal of cancer research · 2021Article
- Proteomic Characterization of Colorectal Cancer Cells versus Normal-Derived Colon Mucosa Cells: Approaching Identification of Novel Diagnostic Protein Biomarkers in Colorectal Cancer.International journal of molecular sciences · 2020Article
- Reticulocalbin-2 enhances hepatocellular carcinoma proliferation via modulating the EGFR-ERK pathway.Oncogene · 2017Article
- Reticulocalbin 2 correlates with recurrence and prognosis in colorectal cancer.American journal of cancer research · 2017Article
- Microenvironment, oncoantigens, and antitumor vaccination: lessons learned from BALB-neuT mice.BioMed research international · 2014Review
- Possibility of the use of public microarray database for identifying significant genes associated with oral squamous cell carcinoma.Genomics & informatics · 2012Article
- Drug-targeted inhibition of peroxisome proliferator-activated receptor-gamma enhances the chemopreventive effect of anti-estrogen therapy.Oncotarget · 2012Article
- Gene expression profiling and real-time PCR analyses identify novel potential cancer-testis antigens in multiple myeloma.Journal of immunology (Baltimore, Md. : 1950) · 2009Article
- Oncoantigens as anti-tumor vaccination targets: the chance of a lucky strike?Cancer immunology, immunotherapy : CII · 2008Article
- Conserved function of RNF4 family proteins in eukaryotes: targeting a ubiquitin ligase to SUMOylated proteins.The EMBO journal · 2007Article
- The TATA-binding protein regulates maternal mRNA degradation and differential zygotic transcription in zebrafish.The EMBO journal · 2007Article
- The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant.Clinical and vaccine immunology : CVI · 2007Article
- Developing effective tumor vaccines: basis, challenges and perspectives.Frontiers of medicine in China · 2007Article
- Inflammation and breast cancer. Inflammatory component of mammary carcinogenesis in ErbB2 transgenic mice.Breast cancer research : BCR · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeoplastic transformation is a multistep process in which distinct gene products of specific cell regulatory pathways are involved at each stage. Identification of overexpressed genes provides an unprecedented opportunity to address the immune system against antigens typical of defined stages of neoplastic transformation. HER-2/neu/ERBB2 (Her2) oncogene is a prototype of deregulated oncogenic protein kinase membrane receptors. Mice transgenic for rat Her2 (BALB-neuT mice) were studied to evaluate the stage in which vaccines can prevent the onset of Her2 driven mammary carcinomas. As Her2 is not overexpressed in all mammary carcinomas, definition of an additional set of tumor associated antigens (TAAs) expressed at defined stages by most breast carcinomas would allow a broader coverage of vaccination. To address this question, a meta-analysis was performed on two transcription profile studies to identify a set of new TAA targets to be used instead of or in conjunction with Her2.
resultsThe five TAAs identified (Tes, Rcn2, Rnf4, Cradd, Galnt3) are those whose expression is linearly related to the tumor mass increase in BALB-neuT mammary glands. Moreover, they have a low expression in normal tissues and are generally expressed in human breast tumors, though at a lower level than Her2.
conclusionAlthough the number of putative TAAs identified is limited, this pilot study suggests that meta-analysis of expression profiles produces results that could assist in the designing of pre-clinical immunopreventive vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.